Ruffell Lab
@ruffell-lab.bsky.social
Cancer immunology lab at Moffitt Cancer Center investigating the role of dendritic cells and macrophages.
Pinned
Ruffell Lab
@ruffell-lab.bsky.social
· Nov 24
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity
Hänggi et al. investigate how tumor necroptosis regulates anti-tumor immunity and
find an unexpected role for interleukin-1α (IL-1α) release by dying cells in promoting
tumor growth by driving recruit...
www.cell.com
Thrilled to share our story out in Cancer Cell, led by the amazing Kay Hanggi (now on the job market). We show that necrotic forms of cell death and the subsequent release of IL1a drives myeloid-based immune suppression in models of breast cancer. (1/11)
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
Reposted by Ruffell Lab
People with some cancers live longer after COVID vaccination 😮
mRNA vaccines can augment immune checkpoint inhibition efficacy for patients with skin or lung cancers - by globally boosting immune responses 💉🧪⚕️
www.nature.com/articles/d41...
Grippen et al study:
www.nature.com/articles/s41...
mRNA vaccines can augment immune checkpoint inhibition efficacy for patients with skin or lung cancers - by globally boosting immune responses 💉🧪⚕️
www.nature.com/articles/d41...
Grippen et al study:
www.nature.com/articles/s41...
People with some cancers live longer after a COVID vaccine
mRNA vaccines seem to boost the effectiveness of an immune therapy for skin and lung cancer ― in an unexpected way.
www.nature.com
October 22, 2025 at 6:08 PM
People with some cancers live longer after COVID vaccination 😮
mRNA vaccines can augment immune checkpoint inhibition efficacy for patients with skin or lung cancers - by globally boosting immune responses 💉🧪⚕️
www.nature.com/articles/d41...
Grippen et al study:
www.nature.com/articles/s41...
mRNA vaccines can augment immune checkpoint inhibition efficacy for patients with skin or lung cancers - by globally boosting immune responses 💉🧪⚕️
www.nature.com/articles/d41...
Grippen et al study:
www.nature.com/articles/s41...
Reposted by Ruffell Lab
Activation and regulation of cGAS-STING signaling in cancer cells
Activation and regulation of cGAS-STING signaling in cancer cells
Cancer-intrinsic genomic instability drives cytosolic DNA accumulation, triggering cGAS-STING immune signaling. Shim et al. review recent advances in cancer/cGAS-STING crosstalk, with a molecular-level focus on sources of cytosolic DNA and immunoregulatory mechanisms, including their therapeutic implications.
dlvr.it
October 17, 2025 at 10:58 PM
Activation and regulation of cGAS-STING signaling in cancer cells
Reposted by Ruffell Lab
Excited to share our review on Thetis cells and dendritic cells, and their roles in mucosal immunity and tolerance @natimmunol.nature.com rdcu.be/eLtB1
Antigen-presenting cells as arbiters of mucosal tolerance and immunity
Nature Immunology - Brown and colleagues review the heterogeneity of mucosal antigen-presenting cells that orchestrate T cell immunity to intestinal antigens.
urldefense.com
October 17, 2025 at 12:22 PM
Excited to share our review on Thetis cells and dendritic cells, and their roles in mucosal immunity and tolerance @natimmunol.nature.com rdcu.be/eLtB1
Reposted by Ruffell Lab
Now online in Cancer Discovery @aacrjournals.bsky.social: Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer - by Nofar Gumpert, Shira Sagie, @yardenasamuels.bsky.social, and colleagues doi.org/10.1158/2159...
October 13, 2025 at 11:00 AM
Now online in Cancer Discovery @aacrjournals.bsky.social: Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer - by Nofar Gumpert, Shira Sagie, @yardenasamuels.bsky.social, and colleagues doi.org/10.1158/2159...
Reposted by Ruffell Lab
Online Now: Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Di Meo et al. demonstrate that multiple myeloma relapses after CAR T cell therapy frequently express low BCMA levels by quantifying target antigen density on patient samples. SEMA4A regulates MM cell proliferation, migration, tissue infiltration, and osteoclast formation. SEMA4A-directed CAR T cells show superior activity in eradicating BCMAlow MM than BCMA-CAR T cells.
dlvr.it
October 9, 2025 at 6:52 PM
Online Now: Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Reposted by Ruffell Lab
Read more about work just published online in Cancer Discovery @aacrjournals.bsky.social by Iris Mimpen, Thomas Battaglia, Miguel Parra Martinez, Emile Voest, and colleagues at @nkinl.bsky.social below and here: doi.org/10.1158/2159...
September 25, 2025 at 6:32 PM
Read more about work just published online in Cancer Discovery @aacrjournals.bsky.social by Iris Mimpen, Thomas Battaglia, Miguel Parra Martinez, Emile Voest, and colleagues at @nkinl.bsky.social below and here: doi.org/10.1158/2159...
Reposted by Ruffell Lab
🔬Our paper from the @miriammerad.bsky.social lab is now online! This is a story shaped over years of cross-disciplinary endeavor at @sinaiimmuno.bsky.social and labs across the world. 🧵:
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours - Nature
An understanding of the molecular mechanisms promoting the generation of immunoregulatory and tumour-promoting monocytes and macrophages is key to breaking the cycle of tumour myelopoiesis and develop...
www.nature.com
September 22, 2025 at 12:41 PM
🔬Our paper from the @miriammerad.bsky.social lab is now online! This is a story shaped over years of cross-disciplinary endeavor at @sinaiimmuno.bsky.social and labs across the world. 🧵:
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Ruffell Lab
Online now: A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer
A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is characterized by high risks of relapse or metastatic disease. Mattavelli et al. identify a chemokine axis that recruits immunosuppressive monocytes to tumor-draining lymph nodes. By co-targeting this recruitment, the TNBC response to immune checkpoint blockade is augmented and metastasis to the lung is reduced.
dlvr.it
September 15, 2025 at 10:38 PM
Online now: A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer
Reposted by Ruffell Lab
Online now: Integrin CD103 expression in naive CD8+ T cells promotes cytokine-driven acquisition of memory phenotype and effector function
Integrin CD103 expression in naive CD8+ T cells promotes cytokine-driven acquisition of memory phenotype and effector function
Integrin CD103 mediates memory T cell tissue residency by binding E-cadherin-expressing epithelial cells, but why CD103 is also expressed on circulating naive CD8+ T cells has been unclear. Li et al. report that CD103 facilitates the interaction of naive CD8+ T cells with E-cadherin-expressing dendritic cells that in turn provide cytokine-mediated cues to promote their differentiation into memory-phenotype effector T cells.
dlvr.it
September 15, 2025 at 7:55 PM
Online now: Integrin CD103 expression in naive CD8+ T cells promotes cytokine-driven acquisition of memory phenotype and effector function
Reposted by Ruffell Lab
How can we reawaken the body’s own anti-viral defenses to fight brain cancer?
Delighted to share our new study where we now answer this question, led by the brilliant @alvarezprado.bsky.social who is now an independent PI at LIH Luxembourg 👏👏
#BrainTIME 🧠🦠🧪
🧵
www.sciencedirect.com/science/arti...
Delighted to share our new study where we now answer this question, led by the brilliant @alvarezprado.bsky.social who is now an independent PI at LIH Luxembourg 👏👏
#BrainTIME 🧠🦠🧪
🧵
www.sciencedirect.com/science/arti...
September 3, 2025 at 12:56 PM
How can we reawaken the body’s own anti-viral defenses to fight brain cancer?
Delighted to share our new study where we now answer this question, led by the brilliant @alvarezprado.bsky.social who is now an independent PI at LIH Luxembourg 👏👏
#BrainTIME 🧠🦠🧪
🧵
www.sciencedirect.com/science/arti...
Delighted to share our new study where we now answer this question, led by the brilliant @alvarezprado.bsky.social who is now an independent PI at LIH Luxembourg 👏👏
#BrainTIME 🧠🦠🧪
🧵
www.sciencedirect.com/science/arti...
Reposted by Ruffell Lab
Online Now: Lymphoma accelerates T cell and tissue aging
Lymphoma accelerates T cell and tissue aging
Hesterberg et al. show that lymphoma provokes marked and rapid changes in young T cells that recapitulate the transcriptional, epigenetic, and senescent features manifest in aged T cells, including aging-associated alterations in inflammation, proteostasis, and iron homeostasis that also occur in other tissues of lymphoma-bearing individuals.
dlvr.it
August 22, 2025 at 2:17 PM
Online Now: Lymphoma accelerates T cell and tissue aging
Reposted by Ruffell Lab
In the new Resource paper from Sofie Rennen and @victor-bosteels.bsky.social, published in @cp-cellreports.bsky.social, they present a method to reliably annotate them. www.cell.com/cell-reports...
Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways
Rennen et al. provide methods to distinguish homeostatic from immunogenic mature cDC1s,
based on lipid nanoparticle (LNP)-induced maturation. Only the uptake of TLR ligand-
or mRNA-encapsulated LNPs i...
www.cell.com
August 21, 2025 at 5:06 PM
In the new Resource paper from Sofie Rennen and @victor-bosteels.bsky.social, published in @cp-cellreports.bsky.social, they present a method to reliably annotate them. www.cell.com/cell-reports...
Reposted by Ruffell Lab
#InterferonPower! Thrilled for our latest work @cp-cell.bsky.social! With @danielboehmer.bsky.social, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IV😉) #interferons! Free👉 authors.elsevier.com/a/1leKGL7PXu...
August 21, 2025 at 3:20 PM
#InterferonPower! Thrilled for our latest work @cp-cell.bsky.social! With @danielboehmer.bsky.social, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IV😉) #interferons! Free👉 authors.elsevier.com/a/1leKGL7PXu...
Reposted by Ruffell Lab
I am beyond excited and incredibly proud to share that our work is now out in @nature.com This discovery was made possible thanks to the first author Kostas kelepouras, my fantastic lab , and the unique research environment here in Cologne in collaboration with the Hospital bambino Gesu in Rome.
STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD - Nature
Nature - STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD
www.nature.com
August 21, 2025 at 6:12 AM
I am beyond excited and incredibly proud to share that our work is now out in @nature.com This discovery was made possible thanks to the first author Kostas kelepouras, my fantastic lab , and the unique research environment here in Cologne in collaboration with the Hospital bambino Gesu in Rome.
Reposted by Ruffell Lab
Online Now: Dendritic cells function beyond antigen presentation
Dendritic cells function beyond antigen presentation
In this issue of Cancer Cell, Chen et al. identify DNASE1L3-expressing dendritic cells (DCs) as enhancers of anti-tumor immunity. By degrading neutrophil extracellular traps, these DCs promote CD8⁺ T cell infiltration into tumors and enhance checkpoint blockade efficacy, extending DNASE1L3’s known immune regulatory role to physical remodeling of the tumor microenvironment.
dlvr.it
August 18, 2025 at 6:51 PM
Online Now: Dendritic cells function beyond antigen presentation
Reposted by Ruffell Lab
Dendritic cells! What can’t they do?!
In addition to being the surveilling determinants of self vs. non-self, they can degrade NETs, unmasking tumors protected by suppressive neutrophils.
www.sciencedirect.com/science/arti...
In addition to being the surveilling determinants of self vs. non-self, they can degrade NETs, unmasking tumors protected by suppressive neutrophils.
www.sciencedirect.com/science/arti...
DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps
CD8+ T cell exclusion and dysfunction in the tumor microenvironment (TME) are among the most challenging obstacles for anti-PD-(L)1 therapy. Here, we …
www.sciencedirect.com
August 17, 2025 at 4:31 PM
Dendritic cells! What can’t they do?!
In addition to being the surveilling determinants of self vs. non-self, they can degrade NETs, unmasking tumors protected by suppressive neutrophils.
www.sciencedirect.com/science/arti...
In addition to being the surveilling determinants of self vs. non-self, they can degrade NETs, unmasking tumors protected by suppressive neutrophils.
www.sciencedirect.com/science/arti...
Reposted by Ruffell Lab
🚨 Our latest paper is out in @natimmunol.nature.com ! 🧵
Plasmacytoid dendritic cells (pDCs) — the immune system’s IFN-I powerhouses — can change their identity!
Congrats to @rebecaarroyo.bsky.social, our team & collaborators 👏👏
🔗 www.nature.com/articles/s41...
Plasmacytoid dendritic cells (pDCs) — the immune system’s IFN-I powerhouses — can change their identity!
Congrats to @rebecaarroyo.bsky.social, our team & collaborators 👏👏
🔗 www.nature.com/articles/s41...
TNF and type I interferon crosstalk controls the fate and function of plasmacytoid dendritic cells - Nature Immunology
Plasmacytoid dendritic cells are type 1 interferon (IFN-I)-producing antiviral specialists that have been shown to be able to differentiate into conventional dendritic cells. Here the authors show how...
www.nature.com
August 15, 2025 at 4:04 PM
🚨 Our latest paper is out in @natimmunol.nature.com ! 🧵
Plasmacytoid dendritic cells (pDCs) — the immune system’s IFN-I powerhouses — can change their identity!
Congrats to @rebecaarroyo.bsky.social, our team & collaborators 👏👏
🔗 www.nature.com/articles/s41...
Plasmacytoid dendritic cells (pDCs) — the immune system’s IFN-I powerhouses — can change their identity!
Congrats to @rebecaarroyo.bsky.social, our team & collaborators 👏👏
🔗 www.nature.com/articles/s41...
Reposted by Ruffell Lab
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work at the Ravetch lab led to this moment, made possible by an amazing team! 🧵 🪡 www.cell.com/cancer-cell/...
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered
CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor
immunity in patients with ...
www.cell.com
August 15, 2025 at 1:45 PM
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work at the Ravetch lab led to this moment, made possible by an amazing team! 🧵 🪡 www.cell.com/cancer-cell/...
Reposted by Ruffell Lab
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak
Rozalén et al. report that TIM3 in breast cancer drives a specific mechanism of immune escape during micrometastasis. TIM3+ tumor cells exhibit stemness/EMT features and promote immune-evasion by inducing immunosuppressive γδ T cells. TIM3 is a biomarker of poor outcome, and its blockade targets metastasis initiating cells during micrometastasis.
dlvr.it
August 14, 2025 at 6:51 PM
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak
Reposted by Ruffell Lab
It’s out!!!!! We hope our review on aging, immunity, and cancer is helpful.
Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social
So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support
Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social
So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support
August 14, 2025 at 1:17 PM
It’s out!!!!! We hope our review on aging, immunity, and cancer is helpful.
Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social
So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support
Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social
So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support
Reposted by Ruffell Lab
My "Crash Course in …Immunology" is now posted on YouTube youtu.be/nBC9vvlTxF8. Taken from a public lecture @crick.ac.uk on history and basic concepts in immunity. Aimed at the lay public and those seeking an introductory overview.
The Past, Present and Future of Immunology Research – with Caetano Reis e Sousa
YouTube video by Francis Crick Institute
youtu.be
August 4, 2025 at 8:11 PM
My "Crash Course in …Immunology" is now posted on YouTube youtu.be/nBC9vvlTxF8. Taken from a public lecture @crick.ac.uk on history and basic concepts in immunity. Aimed at the lay public and those seeking an introductory overview.
Reposted by Ruffell Lab
Delighted that our paper describing cDC1 states and their distribution in mouse tumours is out today in @eurjimmunol.bsky.social. Many congratulations to Cécile Piot who led this work and brought it to conclusion! onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
August 1, 2025 at 10:21 AM
Delighted that our paper describing cDC1 states and their distribution in mouse tumours is out today in @eurjimmunol.bsky.social. Many congratulations to Cécile Piot who led this work and brought it to conclusion! onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Ruffell Lab
🚀 Excited to share our latest publication!
👉 www.nature.com/articles/s41...
A fantastic collaboration with an incredible team.
#BreastCancer #Neutrophils #TumorMicroenvironment #PARPinhibitors #DNARepair #NatureCommunications #CancerImmunology #CalcinottoLab
👉 www.nature.com/articles/s41...
A fantastic collaboration with an incredible team.
#BreastCancer #Neutrophils #TumorMicroenvironment #PARPinhibitors #DNARepair #NatureCommunications #CancerImmunology #CalcinottoLab
Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition - Nature Communications
Tumor-associated neutrophils exhibit heterogeneity in breast cancer. Here, the authors identify a distinct precursor population (PreNeu) in estrogen receptor-positive tumors. PreNeu suppress homologou...
www.nature.com
July 31, 2025 at 1:53 PM
🚀 Excited to share our latest publication!
👉 www.nature.com/articles/s41...
A fantastic collaboration with an incredible team.
#BreastCancer #Neutrophils #TumorMicroenvironment #PARPinhibitors #DNARepair #NatureCommunications #CancerImmunology #CalcinottoLab
👉 www.nature.com/articles/s41...
A fantastic collaboration with an incredible team.
#BreastCancer #Neutrophils #TumorMicroenvironment #PARPinhibitors #DNARepair #NatureCommunications #CancerImmunology #CalcinottoLab
Reposted by Ruffell Lab
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
Ghisoni et al. profile the immune landscape of 697 ovarian cancers (OCs), identifying
four immune phenotypes linked to prognosis and treatment response. The study demonstrates
that BRCA-dependent TIL:...
www.cell.com
July 31, 2025 at 3:26 PM
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Reposted by Ruffell Lab
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity
Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host
B cells and drive B cell proliferation and differentiation. These Th17 cells require
B cells for sustained immunit...
www.cell.com
July 25, 2025 at 2:51 PM
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!